← All trials
NCT04675021
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 13, 2020
- Primary completion
- Dec 25, 2020
- Completion date
- Dec 25, 2020
- First posted
- Dec 19, 2020
- Last posted
- Dec 19, 2020
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- QuotientCollaborator
- QuotientOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.